Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...

Eli Lilly invests $3B in a Netherlands plant to produce obesity drug orforglipron, creating new jobs. Read more here.

Eli Lilly shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion.

Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the ...

American pharmaceutical company Eli Lilly plans to build a $3bn manufacturing facility at the Leiden Bio Science Park in ...

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

Lilly said the plant will strengthen its global supply chain and expand the capacity for its growing portfolio of oral ...

The Indianapolis-based pharmaceutical company said the new site will manufacture its weight-loss pill, orforglipron, and other oral medicines.

US pharma major Eli Lilly has revealed plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, ...

The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio ...

Along with the company’s investment plans in Puerto Rico, Lilly also announced plans to build a $5 billon manufacturing plant in Goochland County, Virgina, a $1 billion investment in its India-based ...